Estudo de viabilidade do sistema de suporte de memória
Implementação do Sistema de Suporte à Memória: Um Estudo de Viabilidade
The purpose of this study is to determining the feasibility of providing the Memory Support System (MSS) to individuals with mild cognitive impairment (MCI) and their partners at a clinic in Ontario, Canada. This will involve a) collecting information from patients referred to the a memory clinic and geriatric day hospital about the patient's interest in and the patient's preferred method to administer the MSS; and b) a cost analysis related to implementation of the MSS. The study will also measure efficacy outcomes of the MSS regarding program adherence as well as to self-reported IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden among a sample of individuals with MCI and their care partners
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
A survey will be created and sent out to participants with MCI who have expressed interest in participating in research and have been seen at a memory clinic or geriatric day hospital after the initiation of the study. The survey will consist of a Likert scale and open questions related to patient interest in and preferred length of MSS administration and preference for in-person versus virtual administration.
During and after collection of the survey data, a sample of 20 individuals with MCI (ages ≥50) and their care partners will undergo MSS training.
At enrollment in the MSS training, participants with MCI and their care partners will complete measures of cognitive and functional status. Participants and partners will also complete measures of treatment adherence, IADLs, self-efficacy for memory, quality of life, mood, anxiety, and caregiver burden at baseline, treatment end, and 8-week follow-up. Participants will complete the MSS training consisting of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after initial assessment. Training will be offered in English or French. After the intervention, participants and their partners will complete a semi-structured interview, seeking suggestions for improving the MSS, teaching curriculum, and intervention logistics.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Neil Thomas, MD
- Número de telefone: 613-562-6322
- E-mail: nthomas@bruyere.org
Estude backup de contato
- Nome: Nayna Kirubakar
- Número de telefone: 1266 613-562-6262
- E-mail: nkirubakar@bruyere.org
Locais de estudo
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 5C8
- Recrutamento
- Bruyère Health Research Institute
-
Contato:
- Neil Thomas, MD
- Número de telefone: 613-562-6322
- E-mail: nthomas@bruyere.org
-
Contato:
- Nayna Kirubakar
- Número de telefone: 1266 613-562-6262
- E-mail: nkirubakar@bruyere.org
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- diagnosis of single or multi-domain MCI
- Clinical Dementia Rating global (CDR) score of ≤ 0.5
- Montreal Cognitive Assessment score of ≥18
- available contact with a care partner ≥ 2 times weekly
- absence or stable intake of nootropic(s) for ≥ 3 months
Exclusion Criteria:
- visual/hearing impairment and/or history of reading or written inability/disability sufficient to interfere with MSS training
- concurrent participation in another related clinical trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Participantes do Sistema de Suporte à Memória
|
The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Interest in completion of MSS training
Prazo: From study start date up to 19 months.
|
Percentage of participants that complete the feasibility survey and agree or strongly agree with the statement that they are interested in completing MSS training. |
From study start date up to 19 months.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to French Memory Support System Intervention
Prazo: One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from adherence scores from one week after starting treatment (MSS intervention) at treatment end and at 8 weeks after the treatment end. Using an adherence scale from 0 to 10, with 10 being highest and a cut-off score of ≥ 7 points suggesting adherence with the MSS. |
One week after starting the treatment (MSS intervention), at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Center for Epidemiologic Studies Depression Scale
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Depression screening scale using Likert scale. Total score of 0-60 points, with higher scores signifying a worse outcome (higher levels of depression). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Everyday Cognition questionnaire.
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report measure of performance based instrumental activities of daily living. Total score of 23-92, with higher scores indicating a worse outcome. |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Functional Assessment Questionnaire
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based report of performance of instrumental activities of daily living. Total score of 0-30, with higher scores indicating a worse outcome (higher level of dependence). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Quality of Life in Alzheimer Disease
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report quality of life scale. Total score of 13-52, with higher scores indicating a better outcome (better quality of life). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
State-Trait Anxiety Inventory by the Resources for Enhancing Alzheimer's Caregiver Health project
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Self report anxiety scale. Total score of 10-40 with higher scores indicating a worse outcome (higher level of anxiety). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Chronic Disease Self-efficacy Scale
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Selected questions related to memory and cognition from self report scale. Total score of 9-90 with higher scores indicating a better outcomes (higher feeling of self-efficacy). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
|
Caregiver Burden Inventory Short-Form
Prazo: Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Change from baseline scale scores at treatment end and at 8 weeks after treatment end. Informant based scale of level of caregiver burden. Total score of 0-48 with higher scores indicating a worse outcome (higher level of burden). |
Baseline, at completion of the treatment - on average 6 weeks, and at 8 week follow-up after treatment end.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Neil Thomas, MD, Bruyère Health Research Institute.
- Investigador principal: Octavio Santos, PhD, Ottawa Hospital Research Institute, Bruyère Health Research Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- M16-23-024
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified data from the study may be shared with other researchers within the HABIT consortium. Data that may be shared will include the results of the feasibility survey and the scores from the baseline, treatment end and 8 week follow up outcome measures collected from participants who complete MSS training.
Prazo de Compartilhamento de IPD
Data will be available after the end date of the study and kept indefinitely.
Critérios de acesso de compartilhamento IPD
Upon request that is approved by the study principal investigators.
Tipo de informação de suporte de compartilhamento de IPD
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .